Tekla Life Sciences Stock Market Value
| HQL Stock | USD 16.65 0.01 0.06% |
| Symbol | Tekla |
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. Market participants price Tekla higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Tekla Life assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 2.594 | Dividend Share 1.82 | Earnings Share 2.79 | Revenue Per Share | Quarterly Revenue Growth (0.70) |
Tekla Life Sciences's market price often diverges from its book value, the accounting figure shown on Tekla's balance sheet. Smart investors calculate Tekla Life's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Tekla Life's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Tekla Life 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Tekla Life's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Tekla Life.
| 11/30/2025 |
| 02/28/2026 |
If you would invest 0.00 in Tekla Life on November 30, 2025 and sell it all today you would earn a total of 0.00 from holding Tekla Life Sciences or generate 0.0% return on investment in Tekla Life over 90 days. Tekla Life is related to or competes with Cion Investment, BlackRock TCP, Gladstone Capital, GigCapital7 Corp, Eagle Point, PennantPark Investment, and Source Capital. Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC More
Tekla Life Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Tekla Life's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Tekla Life Sciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.11 | |||
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 5.46 | |||
| Value At Risk | (2.11) | |||
| Potential Upside | 1.8 |
Tekla Life Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tekla Life's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Tekla Life's standard deviation. In reality, there are many statistical measures that can use Tekla Life historical prices to predict the future Tekla Life's volatility.| Risk Adjusted Performance | 0.0312 | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.09) | |||
| Sortino Ratio | (0.04) | |||
| Treynor Ratio | 0.067 |
Tekla Life February 28, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0312 | |||
| Market Risk Adjusted Performance | 0.077 | |||
| Mean Deviation | 0.8594 | |||
| Semi Deviation | 1.07 | |||
| Downside Deviation | 1.11 | |||
| Coefficient Of Variation | 2730.09 | |||
| Standard Deviation | 1.13 | |||
| Variance | 1.27 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.09) | |||
| Sortino Ratio | (0.04) | |||
| Treynor Ratio | 0.067 | |||
| Maximum Drawdown | 5.46 | |||
| Value At Risk | (2.11) | |||
| Potential Upside | 1.8 | |||
| Downside Variance | 1.22 | |||
| Semi Variance | 1.14 | |||
| Expected Short fall | (0.90) | |||
| Skewness | 0.0602 | |||
| Kurtosis | 0.1092 |
Tekla Life Sciences Backtested Returns
Tekla Life Sciences owns Efficiency Ratio (i.e., Sharpe Ratio) of close to zero, which indicates the firm had a close to zero % return per unit of risk over the last 3 months. Tekla Life Sciences exposes twenty-nine different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Tekla Life's Semi Deviation of 1.07, risk adjusted performance of 0.0312, and Coefficient Of Variation of 2730.09 to confirm the risk estimate we provide. The entity has a beta of 0.47, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tekla Life's returns are expected to increase less than the market. However, during the bear market, the loss of holding Tekla Life is expected to be smaller as well. At this point, Tekla Life Sciences has a negative expected return of -0.0022%. Please make sure to validate Tekla Life's downside variance, and the relationship between the sortino ratio and accumulation distribution , to decide if Tekla Life Sciences performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.39 |
Poor reverse predictability
Tekla Life Sciences has poor reverse predictability. Overlapping area represents the amount of predictability between Tekla Life time series from 30th of November 2025 to 14th of January 2026 and 14th of January 2026 to 28th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Tekla Life Sciences price movement. The serial correlation of -0.39 indicates that just about 39.0% of current Tekla Life price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.39 | |
| Spearman Rank Test | -0.21 | |
| Residual Average | 0.0 | |
| Price Variance | 0.06 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Tekla Life Correlation, Tekla Life Volatility and Tekla Life Performance module to complement your research on Tekla Life. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Tekla Life technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.